SCHEMBL2622368

SCHEMBL2622368

CC(=O)C1OC1C(=O)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 5/20 0.58
HPGD P15428 2/20 0.51
MEN1 O00255 1/20 0.51
TP53 P04637 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
KMT2A Q03164 1/20 0.51
CES1 P23141 4/20 0.43
CES2 O00748 3/20 0.43
HTT P42858 2/20 0.41
MAPT P10636 1/20 0.41
ALOX15 P16050 1/20 0.41
HBB P68871 1/20 0.41
TSHR P16473 2/20 0.39
DAO P14920 1/20 0.39
NAPRT Q6XQN6 1/20 0.39
ALDH1A1 P00352 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10942440 0.89 EPHX1 (0.69) EPHX1HPGDMEN1TP53CYP1A2
SCHEMBL11218778 0.83 EPHX1 (0.62) EPHX1HPGDMEN1TP53CYP1A2
SCHEMBL24217720 0.81 EPHX1 (0.38) EPHX1HPGDMEN1TP53CYP1A2
SCHEMBL11631610 0.80 EPHX1 (0.58) EPHX1HPGDMEN1TP53CYP1A2
SCHEMBL11624519 0.80 EPHX1 (0.58) EPHX1HPGDMEN1TP53CYP1A2
SCHEMBL2622378 0.79 EPHX1 (0.53) EPHX1HPGDMEN1TP53CYP1A2
SCHEMBL6047458 0.79 EPHX1 (0.62) EPHX1HPGDMEN1TP53CYP1A2
SCHEMBL5194624 0.79 EPHX1 (0.62) EPHX1HPGDMEN1TP53CYP1A2
SCHEMBL24217718 0.78 PLK1 (0.44) EPHX1HPGDMEN1CYP1A2CYP2C9
SCHEMBL334010 0.75 EPHX1 (0.62) EPHX1HPGDMEN1TP53CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9757407-B2 Treatment of viral infections by modulation of host cell metabolic pathways THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2017-09-12 US disclosed
US-20160346309-A1 TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS UNIV PRINCETON (US) 2016-12-01 US disclosed
US-9029413-B2 Treatment of viral infections by modulation of host cell metabolic pathways THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2015-05-12 US disclosed
US-20130065850-A1 TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2013-03-14 US disclosed
US-8158677-B2 Treatment of viral infections by modulation of host cell metabolic pathways THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2012-04-17 US disclosed
US-20090239830-A1 Treatment of viral infections by modulation of host cell metabolic pathways KADMON CORPORATION, LLC 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239830-A1 Treatment of viral infections by modulation of host cell metabolic pathways GOT2, MAVS, ME3 EPHX1 1058/4885HPGD 706/4885MEN1 4221/4885
US-20160346309-A1 TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS GOT2, MAVS, ME3 EPHX1 1058/4885HPGD 706/4885MEN1 4221/4885
US-20130065850-A1 TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS GOT2, MAVS, ME3 EPHX1 1058/4885HPGD 706/4885MEN1 4221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.